This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

Among children hospitalized with COVID-19 who received remdesivir, most patients only experienced mild transaminitis and normal creatinine concentrations. The use of remdesivir for the treatment of ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.